Please explore our interactive pipeline graphic to discover more about the products we are developing.

 

Avanir Led

NUEDEXTA®

NUEDEXTA is a rational, innovative combination of two well-characterized drugs with decades of clinical use; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor that enables dextromethorphan to reach therapeutic concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain and spinal cord.

 

Pseudobulbar Affect
AVP-923

AVP-923 is a combination of two well-characterized drugs with decades of clinical use: the active ingredient dextromethorphan hydrobromide (the ingredient active in the central nervous system) and quinidine sulfate (a metabolic inhibitor that enables dextromethorphan to reach therapeutic concentrations).

Agitation in Alzheimer's Disease

Avanir initiated a study to investigate the safety, tolerability and efficacy of AVP-923 for the treatment of agitation in patients with Alzheimer's disease in September 2012.

Levodopa Induced Dyskinesia in Parkinson's Disease

In October 2012 Avanir announced that The Michael J. Fox Foundation had awarded the company a grant to evaluate the safety and efficacy of AVP-923 (dextromethorphan hydrobromide and quinidine sulfate) for the treatment of levodopa induced dyskinesia (LID) in Parkinson's disease (PD).

AVP-786
Neuropathic Pain
Major Depressive Disorder
AVP-825
Migraine

Investigator Led

AVP-923
Treatment-Resistant Depression
Autism

NUEDEXTA for the Treatment of Adults With Autism

This investigator initiated study is designed to demonstrate reduced frequency and intensity of maladaptive behaviors as measured by the Aberrant Behavior Checklist (ABC) Irritability subscale in subjects given NUEDEXTA.

This study is being coordinated by Sutter Health and Michael Chez, MD of Sutter Health.

More details on this study can be found on the NIH website.

Bulbar Function

The Experimental Treatment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis (ALS)

This investigator initiated study is designed to determine whether NUEDEXTA is effective in the treatment of symptoms (impaired speech, swallowing, and saliva control) associated with Amyotrophic Lateral Sclerosis (ALS).

This study is being coordinated by the Center for Neurologic Study, the ALS Association and the State Univeristy of New York.

More details on this study can be found on the NIH website.

NUEDEXTA, (dextromethorphan hydrobromide and quinidine sulfate) 20/10 mg capsules, is FDA-approved for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. NUEDEXTA can interact with other medications and cause serious side effects. NUEDEXTA is contraindicated in patients taking certain drugs and in patients with specific cardiovascular risk factors. These are not all the risks from the use of NUEDEXTA. Please see the Important Safety Information and full prescribing information for further details.